 Zenggang Pan
Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 94 | 1.050 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 1059 | 0.900 |
Why?
| | Plasmablastic Lymphoma | 1 | 2018 | 6 | 0.640 |
Why?
| | Erdheim-Chester Disease | 1 | 2017 | 5 | 0.640 |
Why?
| | CD3 Complex | 1 | 2018 | 92 | 0.620 |
Why?
| | Lymphoma, B-Cell | 1 | 2018 | 85 | 0.590 |
Why?
| | Multiple Myeloma | 1 | 2018 | 100 | 0.570 |
Why?
| | Organic Cation Transport Proteins | 1 | 2016 | 28 | 0.570 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2017 | 229 | 0.540 |
Why?
| | Histiocytic Sarcoma | 1 | 2015 | 3 | 0.540 |
Why?
| | Cell Transdifferentiation | 1 | 2015 | 32 | 0.520 |
Why?
| | Lymphoma, Follicular | 1 | 2015 | 29 | 0.520 |
Why?
| | Trans-Activators | 1 | 2016 | 373 | 0.470 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 310 | 0.260 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1384 | 0.230 |
Why?
| | B-Lymphocytes | 2 | 2018 | 770 | 0.200 |
Why?
| | Fatal Outcome | 2 | 2017 | 287 | 0.180 |
Why?
| | Histocytochemistry | 2 | 2018 | 82 | 0.170 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.160 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2017 | 5 | 0.160 |
Why?
| | Chylothorax | 1 | 2017 | 12 | 0.150 |
Why?
| | Middle Aged | 5 | 2018 | 27617 | 0.150 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 14 | 0.150 |
Why?
| | Pleural Effusion | 1 | 2017 | 47 | 0.150 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 7 | 0.150 |
Why?
| | Organic Cation Transporter 2 | 1 | 2016 | 8 | 0.150 |
Why?
| | Genetic Association Studies | 1 | 2018 | 371 | 0.140 |
Why?
| | Gene Rearrangement | 1 | 2017 | 141 | 0.140 |
Why?
| | Aged | 4 | 2018 | 19657 | 0.140 |
Why?
| | S100 Proteins | 1 | 2015 | 35 | 0.130 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 55 | 0.130 |
Why?
| | Biopsy, Fine-Needle | 1 | 2015 | 69 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 267 | 0.130 |
Why?
| | Cell Lineage | 1 | 2016 | 318 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 842 | 0.120 |
Why?
| | Polymerase Chain Reaction | 1 | 2017 | 1012 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 367 | 0.110 |
Why?
| | Antigens, CD | 1 | 2015 | 460 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1390 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2015 | 455 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1781 | 0.110 |
Why?
| | Young Adult | 2 | 2018 | 10793 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1795 | 0.100 |
Why?
| | Male | 7 | 2018 | 57801 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1284 | 0.100 |
Why?
| | Humans | 10 | 2018 | 118972 | 0.100 |
Why?
| | Female | 5 | 2018 | 61564 | 0.100 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1974 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2275 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1022 | 0.080 |
Why?
| | Adolescent | 2 | 2018 | 18480 | 0.080 |
Why?
| | Adult | 3 | 2018 | 31512 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6561 | 0.070 |
Why?
| | Lung | 1 | 2015 | 3664 | 0.050 |
Why?
| | Karyotyping | 1 | 2018 | 102 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2018 | 136 | 0.040 |
Why?
| | Prednisolone | 1 | 2017 | 76 | 0.040 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2017 | 41 | 0.040 |
Why?
| | Vincristine | 1 | 2017 | 99 | 0.040 |
Why?
| | Etoposide | 1 | 2017 | 149 | 0.040 |
Why?
| | Asparaginase | 1 | 2016 | 30 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2017 | 222 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2016 | 126 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 317 | 0.030 |
Why?
| | North America | 1 | 2016 | 266 | 0.030 |
Why?
| | Europe | 1 | 2016 | 356 | 0.030 |
Why?
| | Doxorubicin | 1 | 2017 | 302 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1085 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 356 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1079 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9342 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1691 | 0.030 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2674 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2436 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3174 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3588 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8293 | 0.020 |
Why?
|
|
Pan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|